PATENT CLAIM ANALYSIS

Application Number: 16153193
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-02
Patent Classification: ["514", "619000"]

Abstract:
This invention provides novel 3-amino propanamide selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, androgenic alopecia or other 5 hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

Claim (Index 5):
The method according to  claim 1 , wherein the compound is represented by the structure of any one of the following compounds:

Metadata:
- Claim Count in Document: 5.0
- Percentile: 97.0
- Lexical Diversity: 1.42647
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15135151', '15331751', '15981636', '15135334', '15222734']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.9048995558175426
- 35 USC 102 Novelty (BERT): 0.6735759597028805
- Combined Prediction Score: 0.8817671962060764
- Mean Citation Score: 793.601892
- Max Citation Score: 854.0647
- Similarity Product: 645.8571277530074

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test